A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease
Objective: To present the safety, tolerability and biomarker effects of RG6042 (previously, IONIS-HTTRX) during an open-label extension (OLE) study in adults with early manifest Huntington’s…Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess the onset of action for rimabotulinumtoxinBinjections in the salivary glands for the treatment of sialorrhea. Background: Sialorrhea (drooling) causes significant morbidity including impaired oral…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease
Objective: The study of the benefit of intestinal levodopa/carbidopa infusion(LCIG) in resistant ON-freezing of gait(FOG-ON) that appears after Subthalamic Nucleus Deep Brain Stimulation(NST-DBS) in Parkinson’s…Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study
Objective: To evaluate the effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease who had previously undergone deep brain stimulation (DBS). Background:…Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis
Objective: To characterize the use of inappropriate antipsychotic therapies among residents with Parkinson’s disease psychosis (PDP) in long-term care (LTC) settings in the US. Background:…OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT
Objective: We present a prospective observational-real life study about the use in Movement Disorders Unit´s patients, since its commercialization in Spain (June 2017). Background: The…Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa
Objective: To examine the inhibitory effect of COMT on the plasma pharmacokinetics of levodopa resulting from repeated, once daily, oral administration of an Opicapone (OPC)…Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of demographic characteristics in the efficacy response of levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: Opicapone (OPC), a…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 217
- Next Page »